|Page (1) of 1 - 01/29/13||email article||print page|
Stemline Therapeutics, a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells and tumor bulk, today announced the pricing of its IPO of 3,317,644 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Stemline from the initial public offering are expected to be $33,176,440, before underwriting discounts and commissions and other offering expenses.
|Stemline Therapeutics Announces Pricing of IPO|
Source:GrabNetworks (c). All Rights Reserved